# Title

 Food and Drugs. PART 312â€”INVESTIGATIONAL NEW DRUG APPLICATION


# ID

 CFR-2018-title21-vol5.Pt. 312


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['greater', 'more than', 'lesser', 'within', 'before', 'after', 'prior to', 'at least', 'greater than', 'maximum', 'later than', 'no more than']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Duration    | ['1.0 month', '10.0 day', '30 day', '2.0 year', '1 year', '15.0 day', '60.0 day', '5.0 year', '1.0 year', '30.0 day', '7.0 day']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Condition   | ['subject to', 'until', 'as soon as', 'where', 'not subject to', 'when', 'provided that', 'unless', 'if']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Entities    | ['Import', 'Early', 'Scope', 'Investigator', 'Such', 'Important', 'Emergency', 'Beltsville, MD', 'IND', 'Indirect', 'Requirement', 'Research, Office', 'Treatment', 'Food', 'Active', 'Availability', 'Manufacturing', 'Unexpected', 'Dispute', 'Sponsor', 'Protocol', 'Information', 'Case', 'Reference', 'Review', 'English', 'Applicability', 'Annual', 'Research', 'Expanded', 'Adequate', 'Rockville, MD', 'United States', 'Subject', 'Additional', 'United States Pharmacopeia', 'Guidance', 'Purpose', 'Washington, DC', 'Inactive', 'Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa', 'Health', 'Individual', 'Termination', 'Serious', 'New Drug', 'Direct', 'Study', 'Amendments', 'Chemistry', 'Docket Number', 'G112', 'Independent', 'New', 'Appropriate', 'Rm', 'Assurance', 'Address', 'Adverse'] |
| Date        | ['2018-03-01', '2018-12-01']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                             |
|:--------------|:------------------------------------------------------------------------------------------------------------------------------------|
| before        | investigation and to preclude commercialization of the drug before  it is approved for commercial distribution.                     |
| after         | A sponsor shall not unduly prolong an investigation  after finding that the results of the investigation appear                     |
| at least      | A waiver request is required to contain  at least one of the following: (1) An explanation why                                      |
| after         | FDA shall provide a written determination 30 days  after  FDA receives the IND or earlier.                                          |
| no more than  | a relatively small number of patients, usually involving no more than  several hundred subjects.                                    |
| after         | They are performed  after preliminary evidence suggesting effectiveness of the drug has                                             |
| within        | not reside or have a place of business within the United States, the IND is required to                                             |
| within        | not reside or have a place of business within the United States, the IND is required to                                             |
| maximum       | determining the dose(s) to be administered, the planned maximum dosage, and the duration of individual patient exposure             |
| within        | the new drug substance and drug product are within acceptable chemical and physical limits for the planned                          |
| within        | sponsor shall notify FDA of the new investigator within  30 days of the investigator being added.                                   |
| before        | a new protocol or a change in protocol before  its implementation.                                                                  |
| within        | essential information on the IND that is not within the scope of a protocol amendment, IND safety                                   |
| more than     | as necessary but, to the extent feasible, not more than  every 30 days.                                                             |
| lesser        | Suspected adverse reaction implies a  lesser degree of certainty about causality than adverse reaction,                             |
| greater       | hepatic necrosis would be unexpected (by virtue of greater severity) if the investigator brochure referred only to                  |
| greater       | cerebral vasculitis would be unexpected (by virtue of greater specificity) if the investigator brochure listed only cerebral        |
| later than    | as soon as possible, but in no case later than 15 calendar days after the sponsor determines that                                   |
| after         | in no case later than 15 calendar days after the sponsor determines that the information qualifies for                              |
| later than    | as soon as possible, but in no case later than  15 calendar days after receiving the request.                                       |
| after         | in no case later than 15 calendar days after  receiving the request.                                                                |
| later than    | as soon as possible but in no case later than 7 calendar days after the sponsor's initial receipt                                   |
| after         | in no case later than 7 calendar days after  the sponsor's initial receipt of the information.                                      |
| later than    | as soon as possible, but in no case later than  15 calendar days after the determination is made.                                   |
| after         | in no case later than 15 calendar days after  the determination is made.                                                            |
| within        | A sponsor shall  within 60 days of the anniversary date that the                                                                    |
| after         | An IND goes into effect: (1) Thirty days after FDA receives the IND, unless FDA notifies the                                        |
| after         | investigators named in the IND: (1) Thirty days after FDA receives the IND; or (2) On earlier                                       |
| within        | concurrently, has been conducted, or will take place within a reasonable time agreed upon by the agency;                            |
| before        | and satisfactorily resolve the matter with the sponsor before  issuing the clinical hold order.                                     |
| no more than  | As soon as possible, and  no more than 30 days after imposition of the clinical hold,                                               |
| after         | as possible, and no more than 30 days after imposition of the clinical hold, the Division Director                                  |
| after         | An investigation may only resume  after FDA (usually the Division Director, or the Director's                                       |
| within        | FDA shall respond in writing to the sponsor within 30-calendar days of receipt of the request and                                   |
| after         | general, only initiate an action under this section after first attempting to resolve differences informally or, when               |
| within        | sponsor in writing, and invite correction or explanation within  a period of 30 days.                                               |
| within        | the sponsor does not respond to the notification within  the allocated time, the IND shall be terminated.                           |
| before        | sponsor with an opportunity for a regulatory hearing before FDA under part 16 on the question of                                    |
| within        | request for a regulatory hearing must be made within 10 days of the sponsor's receipt of FDA's                                      |
| after         | inactive status may only resume (1) 30 days after FDA receives the protocol amendment, unless FDA notifies                          |
| before        | (b) &#8220;End-of-Phase 2&#8221; meetings and meetings held  before  submission of a marketing application.                         |
| before        | meetings held near completion of Phase 3 and before submission of a marketing application (&#8220;pre-NDA&#8221; meetings) are      |
| before        | the sponsor, end-of-Phase 2 meetings should be held before major commitments of effort and resources to specific                    |
| at least      | and, if available, tentative labeling for the drug. at least                                                                        |
| after         | and whether their submission will be deferred until after  approval.                                                                |
| at least      | the sponsor should submit to FDA's reviewing division at least 1 month in advance of the meeting the                                |
| after         | and will only make changes in a protocol after notifying the sponsor, except when necessary to protect                              |
| maximum       | the estimated duration of the study and the maximum  number of subjects that will be involved.                                      |
| before        | investigator brochure containing the information described in &#167;&#8201;312.23(a)(5). before                                     |
| later than    | as soon as possible, and in no event later than 5 working days after making the determination that                                  |
| after         | in no event later than 5 working days after making the determination that the investigation should be                               |
| after         | reports required by this part for 2 years after a marketing application is approved for the drug;                                   |
| after         | reports required by this part for 2 years after a marketing application is approved for the drug;                                   |
| prior to      | individual shall document that informed consent was obtained prior to  participation in the study.                                  |
| after         | not approved for such indication, until 2 years after  the investigation is discontinued and FDA is notified.                       |
| after         | provide the sponsor with an adequate report shortly after  completion of the investigator's participation in the investigation.     |
| after         | eligible to receive test articles under this part. after                                                                            |
| after         | (d) If the Commissioner determines,  after the unreliable data submitted by the investigator are                                    |
| before        | shall have an opportunity for a regulatory hearing before FDA under part 16 on the question of                                      |
| after         | (e) If the Commissioner determines,  after the unreliable data submitted by the investigator are                                    |
| greater       | physicians and patients are generally willing to accept greater risks or side effects from products that treat                      |
| prior to      | sponsor may request a meeting with FDA-reviewing officials. prior to                                                                |
| after         | and whether their submission will be deferred until after  approval.                                                                |
| within        | All of the safeguards incorporated  within parts 50, 56, 312, 314, and 600 of                                                       |
| prior to      | safeguards further include the review of animal studies prior to initial human testing (&#167;&#8201;312.23), and the monitoring of |
| within        | manufacturing practices; (ix) The drug is not adulterated within the meaning of section 501(a)(1), (a)(2)(A), (a)(3), (c),          |
| before        | favorable opinion) by an independent ethics committee (IEC) before initiating a study, continuing review of an ongoing              |
| before        | favorable opinion) by an independent ethics committee (IEC) before initiating a study, continuing review of an ongoing              |
| before        | situations when the IEC reviewing the study finds, before initiation of the study, that informed consent is                         |
| at least      | A waiver request is required to contain  at least one of the following: (i) An explanation why                                      |
| after         | an application for marketing approval, for 2 years after an agency decision on that application; (2) If                             |
| after         | an application for marketing approval, for 2 years after an agency decision on that application; (2) If                             |
| after         | be maintained for a period of 2 years after  the shipment.                                                                          |
| before        | shall have an opportunity for a regulatory hearing before  FDA pursuant to part 16.                                                 |
| within        | there is reasonable likelihood that death will occur within a matter of months or in which premature                                |
| before        | available therapeutic options that would ordinarily be tried before resorting to the investigational drug or an explanation         |
| after         | expanded access IND goes into effect 30 days after FDA receives the IND or on earlier notification                                  |
| after         | access use under &#167;&#8201;312.320 may begin 30 days after FDA receives the protocol or upon earlier notification                |
| greater than  | the person from the investigational drug is not greater than the probable risk from the disease or condition;                       |
| before        | emergency that requires the patient to be treated before a written submission can be made, FDA may                                  |
| after         | the FDA Emergency Call Center, 866-300-4374, e-mail: emergency.operations@fda.hhs.gov. after                                        |
| within        | must agree to submit an expanded access submission within 15 working days of FDA's authorization of the                             |
| at least      | drug under expanded access; and (2) There is at least preliminary clinical evidence of effectiveness of the drug,                   |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-----------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.0 year   | (4) Unless FDA specifies a shorter period, charging for expanded access to an investigational drug for treatment use under subpart I of this part may continue for 1 year from the time of FDA authorization.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 30.0 day   | FDA shall provide a written determination 30 days after FDA receives the IND or earlier.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1 year     | The plan should include the following: (a) The rationale for the drug or the research study; (b) the indication(s) to be studied; (c) the general approach to be followed in evaluating the drug; (d) the kinds of clinical trials to be conducted in the first year following the submission (if plans are not developed for the entire year, the sponsor should so indicate); (e) the estimated number of patients to be given the drug in those studies; and (f) any risks of particular severity or seriousness anticipated on the basis of the toxicological data in animals or prior studies in humans with the drug or related drugs.                                                                                                                                              |
| 30.0 day   | The sponsor shall notify FDA of the new investigator within 30 days of the investigator being added.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 30.0 day   | Protocol amendments to add a new investigator or to provide additional information about investigators may be grouped and submitted at 30-day intervals.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 30.0 day   | Information amendments to the IND should be submitted as necessary but, to the extent feasible, not more than every 30 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 15.0 day   | The sponsor must notify FDA and all participating investigators (i.e., all investigators to whom the sponsor is providing drug under its INDs or under any investigator's IND) in an IND safety report of potential serious risks, from clinical trials or any other source, as soon as possible, but in no case later than 15 calendar days after the sponsor determines that the information qualifies for reporting under paragraph (c)(1)(i), (c)(1)(ii), (c)(1)(iii), or (c)(1)(iv) of this section.                                                                                                                                                                                                                                                                                 |
| 15.0 day   | Upon request from FDA, the sponsor must submit to FDA any additional data or information that the agency deems necessary, as soon as possible, but in no case later than 15 calendar days after receiving the request.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 7.0 day    | The sponsor must also notify FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than 7 calendar days after the sponsor's initial receipt of the information.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 15.0 day   | (2) Relevant followup information to an IND safety report must be submitted as soon as the information is available and must be identified as such, i.e., &#8220;Followup IND Safety Report.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (3) If the results of a sponsor's investigation show that an adverse event not initially determined to be reportable under paragraph (c) of this section is so reportable, the sponsor must report such suspected adverse reaction in an IND safety report as soon as possible, but in no case later than 15 calendar days after the determination is made.                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 60.0 day   | A sponsor shall within 60 days of the anniversary date that the IND went into effect, submit a brief report of the progress of the investigation that includes:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (a) Individual study information.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1.0 year   | (c) A description of the general investigational plan for the coming year to replace that submitted 1 year earlier.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 30 day     | (b) An IND goes into effect:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (1) Thirty days after FDA receives the IND, unless FDA notifies the sponsor that the investigations described in the IND are subject to a clinical hold under &#167;&#8201;312.42; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (2) On earlier notification by FDA that the clinical investigations in the IND may begin.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 30 day     | (c) A sponsor may ship an investigational new drug to investigators named in the IND:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (1) Thirty days after FDA receives the IND; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (2) On earlier FDA authorization to ship the drug.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 30.0 day   | As soon as possible, and no more than 30 days after imposition of the clinical hold, the Division Director will provide the sponsor a written explanation of the basis for the hold.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 30.0 day   | If a sponsor of an IND that has been placed on clinical hold requests in writing that the clinical hold be removed and submits a complete response to the issue(s) identified in the clinical hold order, FDA shall respond in writing to the sponsor within 30-calendar days of receipt of the request and the complete response.                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 30.0 day   | Notwithstanding the 30-calendar day response time, a sponsor may not proceed with a clinical trial on which a clinical hold has been imposed until the sponsor has been notified by FDA that the hold has been lifted.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1.0 year   | If all investigations covered by an IND remain on clinical hold for 1 year or more, the IND may be placed on inactive status by FDA under &#167;&#8201;312.45.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 5.0 year   | (x) The IND has remained on inactive status for 5 years or more.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 30.0 day   | (1) If FDA proposes to terminate an IND, FDA will notify the sponsor in writing, and invite correction or explanation within a period of 30 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 10.0 day   | The sponsor's request for a regulatory hearing must be made within 10 days of the sponsor's receipt of FDA's notification of nonacceptance.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 2.0 year   | (a) If no subjects are entered into clinical studies for a period of 2 years or more under an IND, or if all investigations under an IND remain on clinical hold for 1 year or more, the IND may be placed by FDA on inactive status.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1.0 year   | (a) If no subjects are entered into clinical studies for a period of 2 years or more under an IND, or if all investigations under an IND remain on clinical hold for 1 year or more, the IND may be placed by FDA on inactive status.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 30.0 day   | Upon receipt of such notification, the sponsor shall have 30 days to respond as to why the IND should continue to remain active.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 30.0 day   | Notwithstanding the provisions of &#167;&#8201;312.30, clinical investigations under an IND on inactive status may only resume (1) 30 days after FDA receives the protocol amendment, unless FDA notifies the sponsor that the investigations described in the amendment are subject to a clinical hold under &#167;&#8201;312.42, or (2) on earlier notification by FDA that the clinical investigations described in the protocol amendment may begin.                                                                                                                                                                                                                                                                                                                                  |
| 5.0 year   | (e) An IND that remains on inactive status for 5 years or more may be terminated under &#167;&#8201;312.44.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1.0 month  | At least 1 month in advance of an end-of-Phase 2 meeting, the sponsor should submit background information on the sponsor's plan for Phase 3, including summaries of the Phase 1 and 2 investigations, the specific protocols for Phase 3 clinical studies, plans for any additional nonclinical studies, plans for pediatric studies, including a time line for protocol finalization, enrollment, completion, and data analysis, or information to support any planned request for waiver or deferral of pediatric studies, and, if available, tentative labeling for the drug.                                                                                                                                                                                                         |
| 1.0 month  | To permit FDA to provide the sponsor with the most useful advice on preparing a marketing application, the sponsor should submit to FDA's reviewing division at least 1 month in advance of the meeting the following information:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (i) A brief summary of the clinical studies to be submitted in the application.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1.0 year   | The sponsor shall obtain a commitment from the clinical investigator to promptly update this information if any relevant changes occur during the course of the investigation and for 1 year following the completion of the study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 2.0 year   | (c) A sponsor shall retain the records and reports required by this part for 2 years after a marketing application is approved for the drug; or, if an application is not approved for the drug, until 2 years after shipment and delivery of the drug for investigational use is discontinued and FDA has been so notified.                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2.0 year   | (c) A sponsor shall retain the records and reports required by this part for 2 years after a marketing application is approved for the drug; or, if an application is not approved for the drug, until 2 years after shipment and delivery of the drug for investigational use is discontinued and FDA has been so notified.                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2.0 year   | An investigator shall retain records required to be maintained under this part for a period of 2 years following the date a marketing application is approved for the drug for the indication for which it is being investigated; or, if no application is to be filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and FDA is notified.                                                                                                                                                                                                                                                                                                                                                                              |
| 2.0 year   | An investigator shall retain records required to be maintained under this part for a period of 2 years following the date a marketing application is approved for the drug for the indication for which it is being investigated; or, if no application is to be filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and FDA is notified.                                                                                                                                                                                                                                                                                                                                                                              |
| 1.0 year   | The clinical investigator shall promptly update this information if any relevant changes occur during the course of the investigation and for 1 year following the completion of the study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 2.0 year   | A sponsor or applicant must retain the records required by this section for a foreign clinical study not conducted under an IND as follows:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (1) If the study is submitted in support of an application for marketing approval, for 2 years after an agency decision on that application;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (2) If the study is submitted in support of an IND but not an application for marketing approval, for 2 years after the submission of the IND.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2.0 year   | A sponsor or applicant must retain the records required by this section for a foreign clinical study not conducted under an IND as follows:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (1) If the study is submitted in support of an application for marketing approval, for 2 years after an agency decision on that application;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (2) If the study is submitted in support of an IND but not an application for marketing approval, for 2 years after the submission of the IND.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2.0 year   | Records of shipments under paragraph (a)(1)(i) of this section are to be maintained for a period of 2 years after the shipment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1.0 year   | In all cases of expanded access, sponsors are responsible for submitting IND safety reports and annual reports (when the IND or protocol continues for 1 year or longer) to FDA as required by &#167;&#167;&#8201;312.32 and 312.33, ensuring that licensed physicians are qualified to administer the investigational drug for the expanded access use, providing licensed physicians with the information needed to minimize the risk and maximize the potential benefits of the investigational drug (the investigator's brochure must be provided if one exists for the drug), maintaining an effective IND for the expanded access use, and maintaining adequate drug disposition records and retaining records in a manner consistent with the requirements of &#167;&#8201;312.57. |
| 30.0 day   | An expanded access IND goes into effect 30 days after FDA receives the IND or on earlier notification by FDA that the expanded access use may begin.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 30.0 day   | (ii) Expanded access use under &#167;&#8201;312.320 may begin 30 days after FDA receives the protocol or upon earlier notification by FDA that use may begin.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |


## Condition

| Condition      | Context                                                                                                                                                |
|:---------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------|
| unless         | Regulations are to chapter I of title 21, unless  otherwise noted.                                                                                     |
| subject to     | to all clinical investigations of products that are subject to section 505 of the Federal Food, Drug, and                                              |
| if             | is exempt from the requirements of this part if all the following apply: (i) The investigation is                                                      |
| if             | is exempt from the requirements of this part if all the following apply: (i) The investigation is                                                      |
| if             | is exempt from the requirements of this part if (a) it is intended to be used in                                                                       |
| if             | is exempt from the requirements of this part if  shipped in accordance with &#167;&#8201;312.160.                                                      |
| if             | is exempt from the requirements of this part if the investigation does not otherwise require submission of                                             |
| subject to     | to in vivo bioavailability studies in humans is subject to  the provisions of &#167;&#8201;320.31.                                                     |
| when           | 201 of the Act apply to those terms when used in this part: (b) The following definitions                                                              |
| subject to     | as defined in &#167;&#8201;56.102(g) of this chapter and subject to the requirements of part 56 of this chapter,                                       |
| unless         | The sponsor does not actually conduct the investigation  unless  the sponsor is a sponsor-investigator.                                                |
| if             | (4) FDA will withdraw authorization to charge  if it determines that charging is interfering with the                                                  |
| if             | the drug has a potential clinical benefit that, if demonstrated in the clinical investigations, would provide a                                        |
| if             | to receive the drug under the treatment use, if  there is a limitation.                                                                                |
| unless         | 1 year from the time of FDA authorization. unless                                                                                                      |
| when           | (d) Costs recoverable  when  charging for an investigational drug.                                                                                     |
| if             | or other costs that would be incurred even if the clinical trial or treatment use for which                                                            |
| if             | consistent with the requirements of paragraphs (d)(1) and, if  applicable, (d)(2) of this section.                                                     |
| if             | (b) FDA may grant a waiver  if it finds that the sponsor's noncompliance would not                                                                     |
| if             | A sponsor shall submit an IND to FDA if the sponsor intends to conduct a clinical investigation                                                        |
| subject to     | investigation with an investigational new drug that is subject to  &#167;&#8201;312.2(a).                                                              |
| subject to     | A sponsor shall not begin a clinical investigation subject to  &#167;&#8201;312.2(a) until the investigation is                                        |
| until          | not begin a clinical investigation subject to &#167;&#8201;312.2(a) until the investigation is subject to an IND which                                 |
| subject to     | A sponsor shall not begin a clinical investigation subject to  &#167;&#8201;312.2(a) until the investigation is                                        |
| if             | the side effects associated with increasing doses, and, if  possible, to gain early evidence on effectiveness.                                         |
| subject to     | tool, an investigational new drug that is already subject to a manufacturer's IND or marketing application should follow                               |
| if             | follow the same general format, but ordinarily may, if authorized by the manufacturer, refer to the manufacturer's                                     |
| not subject to | A sponsor-investigator who uses an investigational drug  not subject to a manufacturer's IND or marketing application is ordinarily                    |
| unless         | to submit all technical information supporting the IND, unless such information may be referenced from the scientific                                  |
| subject to     | sponsor who intends to conduct a clinical investigation subject to this part shall submit an &#8220;Investigational New Drug                           |
| until          | (iii) A commitment not to begin clinical investigations  until  an IND covering the investigations is in effect.                                       |
| if             | and address of the contract research organization, ident if ication of the clinical study, and a listing                                               |
| if             | with the drug, with reference to other IND's if pertinent, and to investigational or marketing experience in                                           |
| if             | any reason related to safety or effectiveness, ident if ication of the country(ies) where the drug was                                                 |
| where          | to safety or effectiveness, identification of the country(ies) where the drug was withdrawn and the reasons for                                        |
| if             | substance and the formulation, including the structural formula, if  known.                                                                            |
| if             | biological disposition of the drug in animals and, if  known, in humans.                                                                               |
| when           | published articles on such studies may be appended when  useful.)                                                                                      |
| if             | should be designed in such a way that, if the sponsor anticipates that some deviation from the                                                         |
| if             | the kind of control group to be used, if any, and a description of methods to be                                                                       |
| until          | drug substance and drug product are not expected until  the end of the investigational process.                                                        |
| if             | the planned duration of the proposed clinical investigation, if very short-term tests are proposed, the supporting stability                           |
| where          | which are used in the manufacturing process, and, where applicable, the quantitative composition of the investigational drug                           |
| where          | begin the proposed investigations and a statement of where  the investigations were conducted and                                                      |
| where          | begin the proposed investigations and a statement of where  the investigations were conducted and                                                      |
| if             | absorption, distribution, metabolism, and excretion of the drug, if  known.                                                                            |
| subject to     | (iii) For each nonclinical laboratory study  subject to the good laboratory practice regulations under part 58,                                        |
| if             | good laboratory practice regulations in part 58, or, if the study was not conducted in compliance with                                                 |
| if             | of previous human experience known to the applicant, if  any, with the investigational drug.                                                           |
| if             | the proposed investigation or to the investigation's rationale. if                                                                                     |
| if             | should be provided for each active drug component. if                                                                                                  |
| if             | However,  if any component in such combination is subject to                                                                                           |
| subject to     | However, if any component in such combination is  subject to an approved marketing application or is otherwise lawfully                                |
| unless         | submit published material concerning that active drug component unless such material relates directly to the proposed investigational                  |
| if             | for reasons potentially related to safety or effectiveness. if                                                                                         |
| where          | by name, reference number, volume, and page number where  the information can be found.                                                                |
| subject to     | on the cover sheet that the investigation is subject to  the requirements in &#167;&#8201;50.24 of this chapter.                                       |
| when           | A sponsor shall submit a protocol amendment  when a new investigator is added to carry out                                                             |
| when           | A sponsor shall submit a protocol amendment  when a new investigator is added to carry out                                                             |
| if             | (2) Reference,  if  necessary, to spec                                                                                                                 |
| if             | a request for such comment and the spec if ic questions FDA's response should address.                                                                 |
| when           | (e) When submitted. when                                                                                                                               |
| if             | an information amendment, a request for such comment. if                                                                                               |
| when           | (c) When submitted. when                                                                                                                               |
| if             | event or suspected adverse reaction is considered &#8220;l if e-threatening&#8221;                                                                     |
| if             | event or suspected adverse reaction is considered &#8220;serious&#8221; if , in the view of either the investigator                                    |
| when           | life-threatening, or require hospitalization may be considered serious when , based upon appropriate medical judgment, they may                        |
| if             | event or suspected adverse reaction is considered &#8220;unexpected&#8221; if it is not listed in the investigator brochure                            |
| if             | event or suspected adverse reaction is considered &#8220;unexpected&#8221; if it is not listed in the investigator brochure                            |
| if             | would be unexpected (by virtue of greater severity) if the investigator brochure referred only to elevated hepatic                                     |
| if             | would be unexpected (by virtue of greater spec if icity)                                                                                               |
| as soon as     | risks, from clinical trials or any other source, as soon as possible, but in no case later than 15                                                     |
| if             | adverse event as a suspected adverse reaction only if there is evidence to suggest a causal relationship                                               |
| as soon as     | data or information that the agency deems necessary, as soon as possible, but in no case later than 15                                                 |
| as soon as     | any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than 7                                    |
| if             | sponsor may also propose and adopt a d if ferent reporting format or frequency                                                                         |
| if             | However,  if a serious and unexpected adverse event occurs for                                                                                         |
| if             | However,  if a serious and unexpected adverse event occurs for                                                                                         |
| as soon as     | to an IND safety report must be submitted as soon as the information is available and must be identified                                               |
| if             | the information is available and must be ident if ied as such, i.e., &#8220;Followup IND Safety Report.&#8221;                                         |
| as soon as     | to an IND safety report must be submitted as soon as the information is available and must be identified                                               |
| if             | (3) If the study has been completed, or  if interim results are known, a brief description of                                                          |
| if             | (3) If the study has been completed, or  if interim results are known, a brief description of                                                          |
| if             | (5) A brief description of what,  if anything, was obtained that is pertinent to an                                                                    |
| if             | revision and a copy of the new brochure. if                                                                                                            |
| if             | requests or expects a reply, comment, or meeting. if                                                                                                   |
| if             | IND is withdrawn, FDA shall be so not if ied, all clinical investigations conducted under the IND                                                      |
| if             | Boards, together with the reasons for such withdrawal. if                                                                                              |
| if             | drug may be used in a clinical investigation if the following conditions are met: (1) The sponsor                                                      |
| unless         | (1) Thirty days after FDA receives the IND, unless FDA notifies the sponsor that the investigations described                                          |
| subject to     | that the investigations described in the IND are subject to a clinical hold under &#167;&#8201;312.42; or (2) On                                       |
| until          | administer an investigational new drug to human subjects until the IND goes into effect under paragraph (b)                                            |
| unless         | ongoing clinical investigations or response to the agency. unless                                                                                      |
| unless         | be taken off therapy involving the investigational drug unless specifically permitted by FDA in the interest of                                        |
| if             | or ongoing Phase 1 investigation on clinical hold if it finds that: (i) Human subjects are or                                                          |
| where          | or diseases&#8221; are defined as &#8220;diseases or conditions where the likelihood of death is high unless the                                       |
| unless         | conditions where the likelihood of death is high unless the course of the disease is interrupted.&#8221; The                                           |
| if             | Phase 2 or 3 investigation on clinical hold if it finds that: (i) Any of the conditions                                                                |
| if             | IND or treatment use protocol on clinical hold if it is determined that: (A) The pertinent criteria                                                    |
| if             | IND or expanded access protocol on clinical hold if it is determined that the pertinent criteria in                                                    |
| if             | to be adequate and well-controlled on clinical hold if it finds that: (i) Any of the conditions                                                        |
| if             | under &#167;&#8201;50.24 of this chapter on clinical hold if it is determined that: (i) Any of the                                                     |
| if             | under &#167;&#8201;50.23(d) of this chapter on clinical hold if it is determined that: (i) Any of the                                                  |
| unless         | for the imposition of clinical hold FDA will, unless patients are exposed to immediate and serious risk,                                               |
| when           | Resumption of the affected investigation(s) will be authorized  when the sponsor corrects the deficiency(ies) previously cited or                      |
| until          | on which a clinical hold has been imposed until the sponsor has been notified by FDA that                                                              |
| when           | after first attempting to resolve differences informally or, when appropriate, through the clinical hold procedures described in                       |
| if             | propose to terminate an IND during Phase 1 if it finds that: (i) Human subjects would be                                                               |
| if             | an IND during Phase 2 or Phase 3 if FDA finds that: (i) Any of the conditions                                                                          |
| if             | FDA may propose to terminate a treatment IND if it finds that: (i) Any of the conditions                                                               |
| if             | proposes to terminate an IND, FDA will not if y the sponsor in writing, and invite correction                                                          |
| if             | question of whether the IND should be terminated. if                                                                                                   |
| if             | Notwithstanding paragraphs (a) through (c) of this section,  if at any time FDA concludes that continuation of                                         |
| subject to     | An IND so terminated is  subject to reinstatement by the Director on the basis of                                                                      |
| if             | 2 years or more under an IND, or if all investigations under an IND remain on clinical                                                                 |
| if             | 2 years or more under an IND, or if all investigations under an IND remain on clinical                                                                 |
| if             | inactive status, all investigators shall be so not if ied and all stocks of the drug shall                                                             |
| if             | Additional information supporting the proposed investigation,  if  any, shall be submitted in an information amendment.                                |
| unless         | 30 days after FDA receives the protocol amendment, unless FDA notifies the sponsor that the investigations described                                   |
| subject to     | that the investigations described in the amendment are subject to a clinical hold under &#167;&#8201;312.42, or (2) on                                 |
| if             | the Phase 1 and 2 investigations, the spec if ic protocols for Phase 3 clinical studies, plans                                                         |
| until          | product and whether their submission will be deferred until  after approval.                                                                           |
| when           | the matter directly with the responsible reviewing officials. when                                                                                     |
| subject to     | chapter applicable to this obligation and shall be subject to the same regulatory action as a sponsor for                                              |
| if             | the investigator; (ii) The name and code number, if  any, of the protocol(s) in the IND ident                                                          |
| where          | any medical school, hospital, or other research facility where the clinical investigation(s) will be conducted; (iv) The                               |
| when           | in a protocol after notifying the sponsor, except when necessary to protect the safety, the rights, or                                                 |
| subject to     | commitment by the investigator that, for an investigation subject to an institutional review requirement under part 56, an                             |
| where          | changes in the research without IRB approval, except where necessary to eliminate apparent immediate hazards to the                                    |
| if             | and the number to be employed as controls, if any; the clinical uses to be investigated; characteristics                                               |
| if             | the clinical investigator to promptly update this information if any relevant changes occur during the course of                                       |
| when           | sponsor also shall monitor such investigations to identify when an IRB determines that it cannot approve the                                           |
| as soon as     | The sponsor shall discontinue the investigation  as soon as possible, and in no event later than 5                                                     |
| subject to     | records concerning all other financial interests of investigators subject to  part 54 of this chapter.                                                 |
| if             | marketing application is approved for the drug; or, if an application is not approved for the drug,                                                    |
| until          | an application is not approved for the drug, until 2 years after shipment and delivery of the                                                          |
| subject to     | chapter, obtain the informed consent of each human subject to whom the drug is administered, except as provided                                        |
| if             | indication for which it is being investigated; or, if  no application is to be filed or                                                                |
| if             | indication for which it is being investigated; or, if  no application is to be filed or                                                                |
| until          | the application is not approved for such indication, until 2 years after the investigation is discontinued and                                         |
| unless         | must be reported in accordance with the protocol unless there is evidence suggesting a causal relationship between                                     |
| if             | The clinical investigator shall promptly update this information  if any relevant changes occur during the course of                                   |
| where          | changes in the research without IRB approval, except where necessary to eliminate apparent immediate hazards to human                                  |
| unless         | investigator is not required to divulge subject names unless the records of particular individuals require a more                                      |
| unless         | investigator is not required to divulge subject names unless the records of particular individuals require a more                                      |
| subject to     | If the investigational drug is  subject to the Controlled Substances Act, the investigator shall take                                                  |
| if             | option of the investigator, in an informal conference. if                                                                                              |
| if             | information, including any explanation presented by the investigator, if the Commissioner determines that the investigator has repeatedly              |
| subject to     | be ineligible to receive FDA-regulated test articles is subject to examination to determine whether the investigator has submitted                     |
| if             | to continue the investigation, the Commissioner will not if y the sponsor, who shall have an opportunity                                               |
| if             | which the data were submitted cannot be just if ied, the Commissioner will proceed to withdraw approval                                                |
| when           | of this section may be reinstated as eligible when the Commissioner determines that the investigator has presented                                     |
| where          | treat persons with life-threatening and severely-debilitating illnesses, especially where  no satisfactory alternative therapy exists.                 |
| subject to     | drugs, the many kinds of drugs that are subject to them, and the wide range of uses for                                                                |
| where          | the term &#8220;life-threatening&#8221; means: (1) Diseases or conditions where the likelihood of death is high unless the                             |
| unless         | conditions where the likelihood of death is high unless the course of the disease is interrupted; and                                                  |
| where          | the term &#8220;life-threatening&#8221; means: (1) Diseases or conditions where the likelihood of death is high unless the                             |
| until          | required and whether their submission will be deferred until  after approval.                                                                          |
| if             | Such a treatment protocol,  if requested and granted, would normally remain in effect                                                                  |
| if             | this chapter or the biological product licensing procedures. if                                                                                        |
| subject to     | the procedures contained in this section will be subject to the requirements and procedures contained in part 314                                      |
| if             | States complies with the requirements of this part if it is subject to an IND that is                                                                  |
| subject to     | the requirements of this part if it is subject to an IND that is in effect for it                                                                      |
| if             | States complies with the requirements of this part if it is subject to an IND that is                                                                  |
| if             | The cert if ication shall describe the drug that is to                                                                                                 |
| where          | of a national emergency in a foreign country, where the national emergency necessitates exportation of an investigational                              |
| where          | of a national emergency in a foreign country, where the national emergency necessitates exportation of an investigational                              |
| where          | There may be instances  where exportation of an investigational new drug is needed                                                                     |
| if             | made available for use by the importing country if  and when a national emergency arises.                                                              |
| when           | for use by the importing country if and when  a national emergency arises.                                                                             |
| provided that  | (b)(4)(vi), (b)(4)(vii), (b)(4)(viii), and/or (b)(4)(ix) of this section, provided that he or she: (1) Provides a written statement                    |
| until          | (B) Exportation may not proceed  until FDA has authorized exportation of the investigational new                                                       |
| if             | FDA may deny authorization  if the statements provided under paragraphs (b)(5)(i)(A)(1) or (b)(5)(i)(A)(2)                                             |
| if             | FDA may deny authorization  if the statements provided under paragraphs (b)(5)(i)(A)(1) or (b)(5)(i)(A)(2)                                             |
| where          | (ii) Situations  where the investigational new drug is to be used                                                                                      |
| where          | There may be instances  where exportation of an investigational new drug is needed                                                                     |
| provided that  | (b)(4)(iv), (b)(4)(v), (b)(4)(vi), (b)(4)(vii), (b)(4)(viii), (b)(4)(ix), and/or (b)(4)(xi), provided that he or she: (1) Provides a written statement |
| if             | foreign clinical study not conducted under an IND, if the following conditions are met: (i) The study                                                  |
| if             | the subject (or a subject's legally authorized representative, if the subject is unable to provide informed consent)                                   |
| when           | does not require informed consent in life-threatening situations when the IEC reviewing the study finds, before initiation                             |
| if             | GCP does not require informed consent in l if e-threatening situations when the IEC reviewing the study                                                |
| where          | a cross-reference to another section of the submission where the information is located: (1) The investigator's qualifications;                        |
| if             | the information is located: (1) The investigator's qual if ications; (2) A description of the research facilities;                                     |
| if             | and well controlled under &#167;&#8201;314.126 of this chapter; if                                                                                     |
| if             | statement, including records of the names and qual if ications of IEC members, and make these records                                                  |
| if             | (2) FDA may grant a waiver  if it finds that doing so would be in                                                                                      |
| if             | 2 years after the submission of the IND. if                                                                                                            |
| if             | 2 years after the submission of the IND. if                                                                                                            |
| unless         | drug application will not be disclosed by FDA unless  it has previously been publicly disclosed or acknowledged.                                       |
| if             | in animals used only for laboratory research purposes if  it is labeled as follows:                                                                    |
| if             | vitro diagnostic use that is listed in &#167;&#8201;312.2(b)(2)(ii) if  it is labeled as follows:                                                      |
| if             | authorization to ship a drug under this section if it finds that: (1) The sponsor of the                                                               |
| where          | use of investigational new drugs and approved drugs where availability is limited by a risk evaluation and                                             |
| when           | by a risk evaluation and mitigation strategy (REMS) when the primary purpose is to diagnose, monitor, or                                               |
| when           | drugs to patients with serious diseases or conditions when there is no comparable or satisfactory alternative therapy                                  |
| if             | day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe                                        |
| if             | to pertinent information contained in an existing IND if the sponsor of the existing IND grants a                                                      |
| where          | of therapy; (v) A description of the facility where the drug will be manufactured; (vi) Chemistry, manufacturing,                                      |
| if             | box on Form FDA 1571 must be checked. if                                                                                                               |
| if             | and 312.33, ensuring that licensed physicians are qual if ied to administer the investigational drug for the                                           |
| when           | the emergency procedures described in &#167;&#8201;312.310(d) may begin when the use is authorized by the FDA reviewing                                |
| if             | by the sponsor or by a licensed physician. if                                                                                                          |
| unless         | single course of therapy for a specified duration unless  FDA expressly authorizes multiple courses or chronic therapy.                                |
| if             | to monitor an individual patient expanded access use if  the use is for an extended duration.                                                          |
| when           | protocol for the use under &#167;&#8201;312.315 or &#167;&#8201;312.320. when                                                                          |
| when           | sponsor to consolidate expanded access under this section when the agency has received a significant number of                                         |
| if             | under what circumstances the drug could be developed. if                                                                                               |
| if             | would conduct a clinical trial in these patients. if                                                                                                   |
| if             | the drug is not being actively developed or if the expanded access use is not being developed                                                          |
| if             | the drug is not being actively developed or if the expanded access use is not being developed                                                          |
| if             | interfering with the clinical development of the drug. if                                                                                              |
| when           | and effectiveness to support the expanded access use. when                                                                                             |
| when           | unreasonable and significant risk of illness or injury. when                                                                                           |


## Entities

| Entities                                                                 | Context                                                                                                                                                                                                        |
|:-------------------------------------------------------------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Food                                                                     | Food  and Drugs.                                                                                                                                                                                               |
| Scope                                                                    | Scope .                                                                                                                                                                                                        |
| Applicability                                                            | Applicability .                                                                                                                                                                                                |
| United States                                                            | drug product that is lawfully marketed in the United States is exempt from the requirements of this part                                                                                                       |
| IND                                                                      | IND  means an investigational new drug application.                                                                                                                                                            |
| New Drug                                                                 | with &#8220;Notice of Claimed Investigational Exemption for a New Drug .&#8221;                                                                                                                                |
| Independent                                                              | Independent ethics committee (IEC) means a review panel that                                                                                                                                                   |
| Investigator                                                             | Investigator means an individual who actually conducts a clinical                                                                                                                                              |
| Sponsor                                                                  | Sponsor means a person who takes responsibility for and                                                                                                                                                        |
| Subject                                                                  | Subject means a human who participates in an investigation,                                                                                                                                                    |
| United States                                                            | the statement &#8220;Caution: New Drug&#8212;Limited by Federal (or United States ) law to investigational use.&#8221; (b) The label                                                                           |
| Direct                                                                   | Direct costs include costs per unit to manufacture the                                                                                                                                                         |
| Indirect                                                                 | (ii)  Indirect costs include costs incurred primarily to produce the                                                                                                                                           |
| Requirement                                                              | Requirement  for an IND.                                                                                                                                                                                       |
| Annual                                                                   | Annual reports to the IND should serve as the                                                                                                                                                                  |
| IND                                                                      | IND  content and format.                                                                                                                                                                                       |
| United States                                                            | or have a place of business within the United States , the IND is required to contain the                                                                                                                      |
| United States                                                            | or have a place of business within the United States , the IND is required to contain the                                                                                                                      |
| Reference                                                                | Reference to the current edition of the United States                                                                                                                                                          |
| United States Pharmacopeia                                               | Reference to the current edition of the  United States Pharmacopeia &#8212;National Formulary may satisfy relevant requirements in this                                                                        |
| Reference                                                                | Reference to the current edition of the United States                                                                                                                                                          |
| United States Pharmacopeia                                               | Reference to the current edition of the  United States Pharmacopeia &#8212;National Formulary may satisfy certain requirements in this                                                                         |
| Adequate                                                                 | Adequate information about pharmacological and toxicological studies of the                                                                                                                                    |
| Guidance                                                                 | Guidance documents are available from FDA that describe ways                                                                                                                                                   |
| Such                                                                     | Such information is required to include the identification and                                                                                                                                                 |
| United States                                                            | been investigated or marketed previously, either in the United States or other countries, detailed information about such experience                                                                           |
| United States                                                            | application or is otherwise lawfully marketed in the United States , the sponsor is not required to submit                                                                                                     |
| United States                                                            | If the drug has been marketed outside the United States , a list of the countries in which                                                                                                                     |
| Such                                                                     | Such information shall be submitted in this section as                                                                                                                                                         |
| English                                                                  | The sponsor shall submit an accurate and complete  English translation of each part of the IND that                                                                                                            |
| English                                                                  | The sponsor shall submit an accurate and complete  English translation of each part of the IND that                                                                                                            |
| English                                                                  | of each original literature publication for which an English  translation is submitted.                                                                                                                        |
| New                                                                      | (a)  New  protocol.                                                                                                                                                                                            |
| New                                                                      | (c)  New  investigator.                                                                                                                                                                                        |
| Protocol                                                                 | to be prominently identified as such (i.e., &#8220; Protocol  Amendment: New                                                                                                                                   |
| Protocol                                                                 | Protocol amendments to add a new investigator or to                                                                                                                                                            |
| Information                                                              | Information  amendments.                                                                                                                                                                                       |
| New                                                                      | of information requiring an information amendment include: (1) New toxicology, chemistry, or other technical information; or (2)                                                                               |
| Manufacturing                                                            | identification of its contents (e.g., &#8220;Information Amendment: Chemistry, Manufacturing , and Control&#8221;, &#8220;Information Amendment: Pharmacology-Toxicology&#8221;, &#8220;Information Amendment: |
| Information                                                              | Information amendments to the IND should be submitted as                                                                                                                                                       |
| IND                                                                      | IND  safety reporting.                                                                                                                                                                                         |
| Adverse                                                                  | Adverse event means any untoward medical occurrence associated with                                                                                                                                            |
| Serious                                                                  | Serious  adverse event or serious suspected adverse reaction.                                                                                                                                                  |
| Important                                                                | Important medical events that may not result in death,                                                                                                                                                         |
| Unexpected                                                               | Unexpected  adverse event or unexpected suspected adverse reaction.                                                                                                                                            |
| Unexpected                                                               | &#8220; Unexpected ,&#8221; as used in this definition, also refers                                                                                                                                            |
| United States                                                            | for drugs that are not marketed in the United States .                                                                                                                                                         |
| United States                                                            | of a drug marketed or approved in the United States that is conducted under an IND is required                                                                                                                 |
| Study                                                                    | Study endpoints (e.g., mortality or major morbidity) must be                                                                                                                                                   |
| Annual                                                                   | Annual  reports.                                                                                                                                                                                               |
| Termination                                                              | Termination .                                                                                                                                                                                                  |
| Research                                                                 | Director of the Center for Drug Evaluation and Research or the Director of the Center for Biologics                                                                                                            |
| Inactive                                                                 | Inactive  status.                                                                                                                                                                                              |
| Dispute                                                                  | Dispute  resolution.                                                                                                                                                                                           |
| Appropriate                                                              | Appropriate issues to raise with the ombudsman include resolving                                                                                                                                               |
| Additional                                                               | Additional specific responsibilities of sponsors are described elsewhere in                                                                                                                                    |
| Emergency                                                                | Emergency  research under Â§â€‰50.24 of this chapter.                                                                                                                                                             |
| Rockville, MD                                                            | 1061,  Rockville, MD 20852, copies of the information that was disclosed,                                                                                                                                      |
| Such                                                                     | Such information may be distributed to investigators by means                                                                                                                                                  |
| Important                                                                | Important safety information is required to be relayed to                                                                                                                                                      |
| Review                                                                   | Review  of ongoing investigations.                                                                                                                                                                             |
| Additional                                                               | Additional specific responsibilities of clinical investigators are set forth                                                                                                                                   |
| Case                                                                     | Case histories include the case report forms and supporting                                                                                                                                                    |
| Study                                                                    | Study endpoints that are serious adverse events (e.g., all-cause                                                                                                                                               |
| Assurance                                                                | Assurance  of IRB review.                                                                                                                                                                                      |
| Purpose                                                                  | Purpose .                                                                                                                                                                                                      |
| Scope                                                                    | Scope .                                                                                                                                                                                                        |
| Early                                                                    | Early  consultation.                                                                                                                                                                                           |
| Treatment                                                                | Treatment  protocols.                                                                                                                                                                                          |
| Active                                                                   | Active  monitoring of conduct and evaluation of clinical trials.                                                                                                                                               |
| Import                                                                   | Import  and export requirements.                                                                                                                                                                               |
| United States                                                            | investigational new drug offered for import into the United States complies with the requirements of this part if                                                                                              |
| United States                                                            | investigational new drug offered for import into the United States complies with the requirements of this part if                                                                                              |
| United States                                                            | investigational new drug may be exported from the United States for use in a clinical investigation under any                                                                                                  |
| Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa | (2) The drug has valid marketing authorization in Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa , or in any country in the European                                                 |
| Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa | (2) The drug has valid marketing authorization in Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa , or in any country in the European                                                 |
| Rockville, MD                                                            | (HFG-1), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, at the time the drug is first                                                                                                   |
| United States                                                            | the package is intended for export from the United States ; (vi) The drug is not sold or                                                                                                                       |
| United States                                                            | the package is intended for export from the United States ; (vi) The drug is not sold or                                                                                                                       |
| United States                                                            | the package is intended for export from the United States ; (vi) The drug is not sold or                                                                                                                       |
| Health                                                                   | a written statement showing that the Secretary of Health and Human Services (the Secretary), or his or                                                                                                         |
| Health                                                                   | Emergency Operations and Security Programs, Office of Public Health  Emergency Preparedness, Office of the Secretary, Department of                                                                            |
| Washington, DC                                                           | SW.,  Washington, DC  20201.                                                                                                                                                                                   |
| Health                                                                   | Emergency Operations and Security Programs, Office of Public Health  Emergency Preparedness, Office of the Secretary, Department of                                                                            |
| Washington, DC                                                           | SW.,  Washington, DC  20201.                                                                                                                                                                                   |
| New                                                                      | New insulin and antibiotic drug products may be exported                                                                                                                                                       |
| Availability                                                             | Availability for public disclosure of data and information in                                                                                                                                                  |
| Docket Number                                                            | IND that was required to be filed in Docket Number 95S-0158 in the Division of Dockets Management (HFA-305),                                                                                                   |
| Rockville, MD                                                            | 1061,  Rockville, MD 20852, shall submit a request under the Freedom                                                                                                                                           |
| Address                                                                  | Address  for correspondence.                                                                                                                                                                                   |
| Research                                                                 | submission to the Center for Drug Evaluation and Research (CDER) or to the Center for Biologics Evaluation                                                                                                     |
| Research                                                                 | submission to the Center for Drug Evaluation and Research (CDER) or to the Center for Biologics Evaluation                                                                                                     |
| Research                                                                 | Central Document Room, Center for Drug Evaluation and Research , Food and Drug Administration, 5901-B Ammendale Rd.,                                                                                           |
| Beltsville, MD                                                           | Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266; except send an IND submission for an                                                                                  |
| Research                                                                 | Central Document Room, Center for Drug Evaluation and Research , Food and Drug Administration, 5901-B Ammendale Rd.,                                                                                           |
| Rockville, MD                                                            | Administration, Metro Park North VII, 7620 Standish Pl., Rockville, MD  20855.                                                                                                                                 |
| Research                                                                 | Central Document Room, Center for Drug Evaluation and Research , Food and Drug Administration, 5901-B Ammendale Rd.,                                                                                           |
| Beltsville, MD                                                           | Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD  20705-1266.                                                                                                                      |
| Research                                                                 | and Drug Administration, Center for Biologics Evaluation and Research , Document Control Center, 10903 New Hampshire Ave.,                                                                                     |
| Rm                                                                       | 71,  Rm .                                                                                                                                                                                                      |
| G112                                                                     | G112 , Silver Spring, MD 20993-0002.                                                                                                                                                                           |
| Amendments                                                               | Amendments , reports, and other correspondence relating to matters                                                                                                                                             |
| Rockville, MD                                                            | Affairs, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD  20857.                                                                                                                                |
| Guidance                                                                 | Guidance  documents.                                                                                                                                                                                           |
| Research                                                                 | (b) The Center for Drug Evaluation and  Research  (CDER) and the Center for Biologics Evaluation and                                                                                                           |
| Research                                                                 | (b) The Center for Drug Evaluation and  Research  (CDER) and the Center for Biologics Evaluation and                                                                                                           |
| Research                                                                 | of Drug Information, Center for Drug Evaluation and Research , Food and Drug Administration, 10903 New Hampshire                                                                                               |
| Research, Office                                                         | and Drug Administration, Center for Biologics Evaluation and Research, Office of Communication, Outreach and Development, 10903 New Hampshire                                                                  |
| Rm                                                                       | 71,  Rm .                                                                                                                                                                                                      |
| Serious                                                                  | Serious disease or condition means a disease or condition                                                                                                                                                      |
| Additional                                                               | Additional criteria, submission requirements, and safeguards that apply to                                                                                                                                     |
| Chemistry                                                                | facility where the drug will be manufactured; (vi) Chemistry , manufacturing, and controls information adequate to ensure                                                                                      |
| Individual                                                               | Individual  patients, including for emergency use.                                                                                                                                                             |
| Research                                                                 | regulated by the Center for Biologics Evaluation and Research , the request should be directed to the                                                                                                          |
| Research                                                                 | regulated by the Center for Biologics Evaluation and Research , the request should be directed to the                                                                                                          |
| Research                                                                 | of Drug Information, Center for Drug Evaluation and Research , 301-796-3400, e-mail: druginfo@fda.hhs.gov.                                                                                                     |
| Expanded                                                                 | Expanded access under this section may be needed in                                                                                                                                                            |
| Such                                                                     | Such evidence would ordinarily consist of data from phase                                                                                                                                                      |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2018-12-01 | In such cases:                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (A) A person may export an investigational new drug under paragraph (b)(4) of this section without making an affirmation with respect to any one or more of paragraphs (b)(4)(i), (b)(4)(iv), (b)(4)(v), (b)(4)(vi), (b)(4)(vii), (b)(4)(viii), (b)(4)(ix), and/or (b)(4)(xi), provided that he or she:                                                                                                                   |
|            |               (1) Provides a written statement explaining why compliance with each such paragraph is not feasible or is contrary to the best interests of the individuals who are expected to receive the investigational new drug and                                                                                                                                                                                                  |
|            |               (2) Provides sufficient information from an authorized official of the importing country's government to enable the Secretary, or his or her designee, to decide whether a national emergency has developed or is developing in the importing country, whether the investigational new drug will be used solely for that national emergency, and whether prompt exportation of the investigational new drug is necessary. |
| 2018-03-01 | (i) The drug is an approved drug product that is no longer marketed for safety reasons or is unavailable through marketing due to failure to meet the conditions of the approved application, or                                                                                                                                                                                                                                        |
| 2018-03-01 | (ii) The drug contains the same active moiety as an approved drug product that is unavailable through marketing due to failure to meet the conditions of the approved application or a drug shortage.                                                                                                                                                                                                                                   |


